<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFE5C6FD-3500-44F6-B100-184B5F2FD0D7"><gtr:id>AFE5C6FD-3500-44F6-B100-184B5F2FD0D7</gtr:id><gtr:name>Microsoft Research</gtr:name><gtr:address><gtr:line1>One Microsoft Way</gtr:line1><gtr:line4>Redmond</gtr:line4><gtr:line5>Washington 98052</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/74C9BE1A-DF07-4388-B5F3-BEE269771544"><gtr:id>74C9BE1A-DF07-4388-B5F3-BEE269771544</gtr:id><gtr:name>Royal Institution of Great Britain</gtr:name><gtr:address><gtr:line1>The Royal Institution</gtr:line1><gtr:line2>21 Albemarle Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>W1S 4BS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37E19127-58AE-4048-8C12-1A28A61B9B59"><gtr:id>37E19127-58AE-4048-8C12-1A28A61B9B59</gtr:id><gtr:name>Adaptimmune</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/69417031-F8F1-4557-BF08-49096CDBF321"><gtr:id>69417031-F8F1-4557-BF08-49096CDBF321</gtr:id><gtr:name>University of the Free State</gtr:name><gtr:address><gtr:line1>University of the Free State</gtr:line1><gtr:line2>Nelson Mandela Drive</gtr:line2><gtr:line3>PO Box 339</gtr:line3><gtr:line4>Bloemfontein</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFE5C6FD-3500-44F6-B100-184B5F2FD0D7"><gtr:id>AFE5C6FD-3500-44F6-B100-184B5F2FD0D7</gtr:id><gtr:name>Microsoft Research</gtr:name><gtr:address><gtr:line1>One Microsoft Way</gtr:line1><gtr:line4>Redmond</gtr:line4><gtr:line5>Washington 98052</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/74C9BE1A-DF07-4388-B5F3-BEE269771544"><gtr:id>74C9BE1A-DF07-4388-B5F3-BEE269771544</gtr:id><gtr:name>Royal Institution of Great Britain</gtr:name><gtr:address><gtr:line1>The Royal Institution</gtr:line1><gtr:line2>21 Albemarle Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>W1S 4BS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37E19127-58AE-4048-8C12-1A28A61B9B59"><gtr:id>37E19127-58AE-4048-8C12-1A28A61B9B59</gtr:id><gtr:name>Adaptimmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/69417031-F8F1-4557-BF08-49096CDBF321"><gtr:id>69417031-F8F1-4557-BF08-49096CDBF321</gtr:id><gtr:name>University of the Free State</gtr:name><gtr:address><gtr:line1>University of the Free State</gtr:line1><gtr:line2>Nelson Mandela Drive</gtr:line2><gtr:line3>PO Box 339</gtr:line3><gtr:line4>Bloemfontein</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EAD69D6C-4A04-4567-8945-986175413495"><gtr:id>EAD69D6C-4A04-4567-8945-986175413495</gtr:id><gtr:firstName>Alexander</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Frater</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F626"><gtr:id>87801738-DCD0-41E1-84A1-725287918FD3</gtr:id><gtr:title>The Impact of T Cell Immunity on HIV-1 Diversity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/626</gtr:grantReference><gtr:abstractText>Despite intensive research there is still no effective HIV vaccine. There has been a recent international call to suspend clinical vaccine trials and to concentrate on the underlying molecular biology that determines how and why a vaccine might succeed. This project aims to address these fundamental issues.

HIV has the ability to adapt to its environment in a manner unprecedented in any other organism. This is reflected by the rapid development of resistance to antiviral drugs and by the development of mutations that camouflage the virus from the immune system. This project will demonstrate how, in a population of newly infected HIV positive individuals, the virus that has been transmitted will adapt to a key component of the immune system of the new host and simultaneously revert many of the mutations acquired during infection of the previous host. As patients progress to AIDS we hope to show how the immune system is no longer able to exert any selection pressure on the virus.

We will explore the key components of our immune system to see whether adaptation to one may be disadvantageous to others. If so, the impact of viral evolution on the efficacy of our immune system may be more significant than realised.</gtr:abstractText><gtr:technicalSummary>Aims
This project aims to determine the degree to which HIV is evolving at the population level to adapt to the human immune system.
Objectives
 To explore the impact of HLA on the long-term evolution of HIV within a population.
o To define the evolution of HLA-associated genetic diversity from the time of infection until established chronic infection by tracking HIV sequence variation in a strictly defined group of several hundred seroconverters. 
o To study how the onset of AIDS impacts on the fate of HLA-associated viral mutations.
 To test whether identified polymorphisms facilitate adaptation to both HLA Class I subtypes and ?supertypes?. 
o To assess the functional significance of identified polymorphisms using assays of HLA Class I binding and T cell activation.
o To identify cross-recognition of HIV-1 antigens by multiple HLA Class I subtypes according to the principle of ?supertypes?.
Design
This project will investigate a unique group of predominantly untreated HIV seroconverters that will represent the largest studied cohort of this sort to date. The study will involve both longitudinal and cross-sectional analyses. Stored samples will be tested retrospectively and those from newly recruited patients, prospectively. 

Methodology
We have established collaborations to study four independent patient cohorts. Samples from HIV seroconverters will be tested retrospectively from St. Mary?s Hospital in London (n=105) and from the Swiss HIV cohort (n=100). In addition, new patients will be recruited prospectively from the ?Spartac? seroconverter cohort (total predicted n=450). Chronically infected HIV+ve patients will be recruited from the Free State ARV programme in South Africa (n&amp;gt;2000).

Longitudinal sequence analysis of viral RNA and proviral DNA by population and clonal sequencing will identify patterns of mutation and reversion and, specifically, the evolution of association of HIV polymorphisms with Class I HLA molecules. Bindi assess the interaction between variant peptides and HLA Class I molecules. Functional assays ( -interferon ELISpot) will be used to study the ability of variant peptides to induce an immune response.

Scientific and Medical Opportunities
The project will provide a detailed description of the HIV antigenic challenge. We will gain understanding of the population level evolution of HIV with inferences for changes in pathogenesis of the epidemic. The detailed sequence data will contribute towards understanding the HIV response to vaccine challenge - crucial information that is currently being demanded at an international level to enable the design of a sustainable vaccine.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>788536</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Royal Institution of Great Britain</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Royal Institution and UCL</gtr:description><gtr:id>F4E3B990-01C2-44D1-8B39-945B9D700AB7</gtr:id><gtr:impact>Publication:
Application of magnetic field hyperthermia and superparamagnetic iron oxide nanoparticles to HIV-1-specific T-cell cytotoxicity.
Williams JP, Southern P, Lissina A, Christian HC, Sewell AK, Phillips R, Pankhurst Q, Frater J.
Int J Nanomedicine. 2013;8:2543-54. doi: 10.2147/IJN.S44013. Epub 2013 Jul 23.
PMID: 23901272</gtr:impact><gtr:outcomeId>sBmSyzcVMSN-1</gtr:outcomeId><gtr:partnerContribution>Provision of reagents</gtr:partnerContribution><gtr:piContribution>Analysis of reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>MRC CTU: UK Register of Seroconverters</gtr:description><gtr:id>41EDD721-3964-4DBF-BED9-FD59FB3713F3</gtr:id><gtr:impact>BHIVA Research Award - &amp;pound;30,000
MRC Senior Fellowship</gtr:impact><gtr:outcomeId>Vsr5VKJpvvf-1</gtr:outcomeId><gtr:partnerContribution>To identify and trace potential participants to the UK Heather cohort</gtr:partnerContribution><gtr:piContribution>Collaboration with MRC CTU to analyse HIV reservoir levels in patients with primary HIV infection</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>James Martin 21st Century School</gtr:department><gtr:description>Oxford Martin School</gtr:description><gtr:id>60716822-28CB-48FD-B8A9-7028BC3FE630</gtr:id><gtr:impact>On-going publications from Institute of Emerging Infections, documented in publications section of portfolio</gtr:impact><gtr:outcomeId>LAPugUtGLK7-1</gtr:outcomeId><gtr:partnerContribution>Development of software pipelines and sequencing technologies to inform HIV and HCV cure strategies</gtr:partnerContribution><gtr:piContribution>Collaboration stemming from the Institute of Emerging Infection and resulting in a new round of funding won through a competitive process</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Harvard Medical School</gtr:description><gtr:id>FC049218-8C23-48F2-9EBD-6273E024F453</gtr:id><gtr:impact>DPhil achieved for Gary Huang, under my supervision. Publication: 
Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations.
Huang KH, Goedhals D, Carlson JM, Brockman MA, Mishra S, Brumme ZL, Hickling S, Tang CS, Miura T, Seebregts C, Heckerman D, Ndung'u T, Walker B, Klenerman P, Steyn D, Goulder P, Phillips R; Bloemfontein-Oxford Collaborative Group, van Vuuren C, Frater J.
PLoS One. 2011 Apr 22;6(4):e19018. doi: 10.1371/journal.pone.0019018.
PMID: 21544209</gtr:impact><gtr:outcomeId>hymRmuJHgAi-1</gtr:outcomeId><gtr:partnerContribution>Facilitated on-going research project into HIV viral fitness</gtr:partnerContribution><gtr:piContribution>Provision of reagents for viral fitness assays and collaborative research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Microsoft Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>eScience</gtr:department><gtr:description>Microsoft</gtr:description><gtr:id>A6E23430-DF84-4714-9BBC-5A36FE297A84</gtr:id><gtr:impact>Research outputs (Conference presentation, DPhil). Paper currently in review</gtr:impact><gtr:outcomeId>BKaKnoFwdE8-1</gtr:outcomeId><gtr:partnerContribution>Research outputs, conference abstracts. Paper in review</gtr:partnerContribution><gtr:piContribution>Sharing of data and analytical techniques</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gilead</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Gilead</gtr:description><gtr:id>AC9A2729-DAFD-4020-8FB9-FF906E27BF4A</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:outcomeId>f4tePLvjojq-1</gtr:outcomeId><gtr:partnerContribution>Provision of novel anti-HIV therapy under MTA</gtr:partnerContribution><gtr:piContribution>Investigation of novel anti-HIV therapy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial Clinical Trials Unit (ICTU)</gtr:department><gtr:description>SPARTAC Trial Investigators</gtr:description><gtr:id>94A7BD2A-5EF1-4249-8A4A-DDDF8A26DC39</gtr:id><gtr:impact>We have recently published two papers in the journal of Virology (19019964, 17409157) as well as oral and poster presentations at a number of international meetings. The trial published this year in NEJM: PMID: 23323897</gtr:impact><gtr:outcomeId>B6B5647E20D-1</gtr:outcomeId><gtr:partnerContribution>Access to samples taken from a large cohort of caucasian and African HIV seroconverters enrolled in a trial of short course therapy in acute infection</gtr:partnerContribution><gtr:piContribution>My groups has collaborated with the SPARTAC investigators to determine the degree of HIV viral evolution and immune escape in acute and early HIV infection</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Melbourne</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Department of Microbiology and Immunology</gtr:department><gtr:description>University of Melbourne</gtr:description><gtr:id>B72903EA-3043-4CEE-898C-43241D3F2776</gtr:id><gtr:impact>Work in Progress</gtr:impact><gtr:outcomeId>bsxnh7vBvrR-1</gtr:outcomeId><gtr:partnerContribution>Training and provision of reagents</gtr:partnerContribution><gtr:piContribution>Implementation of viral RNA assay in the lab</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Adaptimmune</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adaptimmune Ltd</gtr:description><gtr:id>5B52ABEC-D7D5-44EB-A8FB-CF3E906DAA02</gtr:id><gtr:impact>MRC Confidence in Concept award - 2013
No publications as yet, although work in progress</gtr:impact><gtr:outcomeId>geVBjv68uyU-1</gtr:outcomeId><gtr:partnerContribution>Industry Partner Collaboration to provide reagents and services.
Services include mass spectrometry and T cell line preparation
Reagents include Adapted TCRs and viral vectors</gtr:partnerContribution><gtr:piContribution>Industry partner. Utilisation of partner's reagents and facilities to expand primary cell models of latency and proof-of-concept strategies for novel HIV interventions.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Infectious Disease and Antimicrobial Resistance</gtr:department><gtr:description>Merck &amp;amp; Co</gtr:description><gtr:id>74E6705C-EE97-4D2C-A511-E3D6A6C620AB</gtr:id><gtr:impact>Recent MRC DCS award ('REACH') in which MERCK is an industry partner</gtr:impact><gtr:outcomeId>nFS4uMTaKE5-1</gtr:outcomeId><gtr:partnerContribution>Provision via MTA of novel anti-HIV therapy</gtr:partnerContribution><gtr:piContribution>Investigation of novel anti-HIV therapy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Free State, Bloemfontein</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Oxford-Bloemfontein Collaborative Group</gtr:description><gtr:id>59CBAE28-1A95-4308-8F6E-1E9C93DABED8</gtr:id><gtr:impact>Recent publication (19918101) in Antiviral Therapy and poster and oral presentations at national and international meetings</gtr:impact><gtr:outcomeId>A3D76DF8698-1</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients with late-stage AIDS infection to a study of viral adaptation in advanced disease</gtr:partnerContribution><gtr:piContribution>We have collaborated with the Free State University to recruit over 1500 patients to a study of viral evolution and drug resistance in patients with advanced HIV infection</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>CHERUB Cooperative: Collaborative HIV Eradication of Reservoirs: UK BRC</gtr:description><gtr:id>A76310F8-F7F0-40BD-A188-269CBB36704A</gtr:id><gtr:impact>Initially funding from the NIHR CBRC renewal across all five CBRCS</gtr:impact><gtr:outcomeId>GPMM2J4LpoC-1</gtr:outcomeId><gtr:partnerContribution>Academic, strategy and intellectual input</gtr:partnerContribution><gtr:piContribution>I am the chair of the CHERUB TSC, the scientific lead and overall co-PI. CHERUB infrastructure has been funded across all five CBRCs as part of a 5-way cooperative agreement</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pennsylvania</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>UPenn</gtr:description><gtr:id>B212498B-0F5F-4F2C-B30C-08503BEC477F</gtr:id><gtr:impact>Williams et al; HIV Cure Symposium 2013; Oral Presentation
Williams et al; IAS 2013; Kuala Lumpur; Oral Presentation</gtr:impact><gtr:outcomeId>RVzskDBm17Q-1</gtr:outcomeId><gtr:partnerContribution>Training of DPhil student
Assistance with development assays in the lab</gtr:partnerContribution><gtr:piContribution>Assistance with HIV viral sequencing
Training of lab member</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Radio Scotland Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7F5296F4-51F8-40E7-9417-7FCC5FB0D743</gtr:id><gtr:impact>Interview on HIV cure research

Broad publicity for research field</gtr:impact><gtr:outcomeId>cT6kTScSt1n</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Interview 5 Live 2012</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>78ADD953-9501-4928-85D1-83A61109ABE4</gtr:id><gtr:impact>Interview on HIV Cure research

Broad publicity for HIV cure research</gtr:impact><gtr:outcomeId>LQFCQGYGVYX</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dalian Summer WEF 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>42C06E01-4609-4372-AA76-D3C3464EA989</gtr:id><gtr:impact>100 business leaders, politicians, academics attended a talk and then a workshop led by me

Excellent feedback and expanded collaborations in non-medical community</gtr:impact><gtr:outcomeId>PUuQB45KkzA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit (Chiping Norton)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>728F42A1-D418-42C7-B0A5-DD6CDD9DB436</gtr:id><gtr:impact>150 students from GCSE to 6th form attended a talk on HIV research and a subsequent discussion on the epidemic

Have been asked to speak again and to a separate talk to the 'gifted and talented' student group.
Also asked to assist with med school interview preparation</gtr:impact><gtr:outcomeId>co5LgFCdt84</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Davos World Economic Forum 2013</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>37C857EE-E538-4B21-9517-0FD1BFB06DDC</gtr:id><gtr:impact>Invited to attend in 2012, for the meeting in January 2013. Presentation within a Think Tank for Oxford Martin School

Well received by delegates in academia and private sector</gtr:impact><gtr:outcomeId>HWij8ncEiSA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford NIHR BRC Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EF46FEDE-8492-4CAD-9A4C-B89666DF7947</gtr:id><gtr:impact>Schools and members of the public visited the stall over the course of the day - at least 100 visitors - to learn about HIV, its treatment and drug resistance.

Broad engagement across schools and general public.</gtr:impact><gtr:outcomeId>VsPQMuc3PxT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society Summer Science Exhibition 2010</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1A0AC631-E723-430D-845F-89BF5C8F831C</gtr:id><gtr:impact>a 9 day festival of science with hundreds of school pupils and members of the public involved in discussion and interactive activities and games

Significant interest discussed in science and medicine amongst school groups</gtr:impact><gtr:outcomeId>gwFfasSVzhG</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Interview (5 Live 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>366522D6-A99F-433E-9757-C566C164359D</gtr:id><gtr:impact>Radio interview on the state of the HIV epidemic in the UK

Reported by Oxford Martin school press release</gtr:impact><gtr:outcomeId>azdFzthr4Gk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IAS Press Conference</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>504B64F9-D8AF-4E7C-992D-FBF2DE839C4E</gtr:id><gtr:impact>Press conference to inform international media of results of reservoir work from the SPARTAC trial and to inform on future work towards an HIV cure

Widespread media reporting eg: 
http://www.hivandhepatitis.com/hiv-treatment/hiv-cure/4206-ias-2013-1the-future-of-hiv-cure-research-video</gtr:impact><gtr:outcomeId>Jj3XWMi6ADH</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=Wo8NdKWVdhU</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>65900</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>Nuffield Dept of Medicine Studentship (for JM, DPhil Student)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>9D406FBF-5884-48A5-8D38-E03295BC83EC</gtr:id><gtr:outcomeId>TEFtgSX3ehY0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>79590</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>John Fell Fund</gtr:department><gtr:description>John Fell Fund</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>CC9FC795-65A0-43D8-98DA-62D253490B01</gtr:id><gtr:outcomeId>WgvNHSGr9ek</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DCS</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L00528X/1</gtr:fundingRef><gtr:id>BA068F70-83AC-4083-98CD-274DBCF6E136</gtr:id><gtr:outcomeId>W6zwXHyDe9z</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>NIHR OXFORD CBRC RENEWAL</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>F9DC4FF0-F650-4D9A-83F0-8DD005CD2405</gtr:id><gtr:outcomeId>TLkJCXywdWx0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CiC</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>74842AAD-8ECF-40DF-B797-B797DB872729</gtr:id><gtr:outcomeId>LVzb8yTRruq</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>John Fell Fund</gtr:department><gtr:description>John Fell Fund, Oxford University Press/Oxford University Press</gtr:description><gtr:end>2007-02-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>E12BCABB-DDE8-4733-9C24-C7C89C04CC47</gtr:id><gtr:outcomeId>RsNG5D8oksB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rhodes Scholarship (For GH, DPhil Student)</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Rhodes Trust</gtr:fundingOrg><gtr:id>B321E627-AE7B-4012-9225-CB9D444C0E69</gtr:id><gtr:outcomeId>gvSiuvF1ys90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>64000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>Nuffield Dept of Medicine Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>D515A2CD-1556-4ED6-8CB6-ABF4C5FDB1C5</gtr:id><gtr:outcomeId>p9Dj9RxMeKL0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Senior Clinical Fellowship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L006588/1</gtr:fundingRef><gtr:id>7DB0D831-EE56-479E-8B2A-99DBDCA94F1D</gtr:id><gtr:outcomeId>54631f48b410b2.30720457</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>512000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>James Martin 21st Century School</gtr:department><gtr:description>James Martin 21st Century School</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>09CCFE5B-4D92-4695-9420-271F72623A1D</gtr:id><gtr:outcomeId>g1ehZECTuHQ0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>64000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rhodes Scholarship (for LM, DPhil Student)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Rhodes Trust</gtr:fundingOrg><gtr:id>5B76A687-5627-4D1E-A933-1AC0A530A822</gtr:id><gtr:outcomeId>Z7e4o59mFP90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>Oxford Biomedical Research Council/Oxford NIHR CBRC</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>F391019A-1DFE-470F-9983-780DFA4611B7</gtr:id><gtr:outcomeId>4378035F58A0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHIVA Research Award</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>British HIV Association (BHIVA)</gtr:fundingOrg><gtr:id>6CF155D0-DFD9-4C2F-9212-16E3C9524423</gtr:id><gtr:outcomeId>mPPuPPZxFsg</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chief Medical Officer Policy Meeting</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2F13FC2F-32CE-4897-9FA9-CBC5F756BECF</gtr:id><gtr:outcomeId>rQSZeFuT27t</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British HIV Association treatment guidelines 2015</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>BHIVA Treatment Guidelines</gtr:guidelineTitle><gtr:id>238E775E-340F-4E0D-9E05-527BF7B94421</gtr:id><gtr:outcomeId>56dc9ea09c3037.59889156</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://WWW.BHIVA.ORG</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Engagement with iBase</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ADEB8BB2-A1AF-4FB0-9D78-E9FF8FAD87F6</gtr:id><gtr:impact>PAtient and public education around HIV from the ibase publication, website and Twitter feed</gtr:impact><gtr:outcomeId>ZCfnJg7jY3E</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Assays to measure the HIV proviral load and ultra-low level viraemia for patients receiving antiretroviral therapy. Assays to be trialed over next 12-36 months for value in application to NHS clinic practice</gtr:description><gtr:id>3D6324E9-866E-4D02-A011-E59B3EFD3072</gtr:id><gtr:impact>Impact pending result of trials to test clinical relevance and application</gtr:impact><gtr:outcomeId>RRtoGEJFCXk</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HIV reservoir assays</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>New use of combination therapy of HDAC inhibitors plus vaccination in primary HIV infection as a strategy to cure HIV. Funded by &amp;pound;1.7 million MRC DCS award.</gtr:description><gtr:id>73F9DE42-991B-4772-93F2-280F9ACBB419</gtr:id><gtr:impact>This combination of therapies is to be trialled in a clinical trial, with recruitment commencing in 2014</gtr:impact><gtr:outcomeId>gYEKotCRVLQ</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HDACi + Vaccination for HIV cure</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Open source software to analyse digital droplet PCR data</gtr:description><gtr:id>9EB5E28C-305D-4A43-8AB7-F8B1F37F2089</gtr:id><gtr:impact>Most downloaded paper from J Virol Methods for first 6 months of 2014</gtr:impact><gtr:outcomeId>546323eda140f0.41492732</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Definetherain</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>NIHR funded pan-CBRC cooperative across Oxford, Cambridge, Imperial, UCL and King's with international networks and industry engagement</gtr:description><gtr:id>CB7CDE76-D984-49BC-9282-573346AD12E1</gtr:id><gtr:impact>Funding in NIHR renewal in 2011 across all five CBRCs for CHERUB infrastructure
Pan-CBRC collaboration between UCL, OXford, Cambridge, King's and Imperial</gtr:impact><gtr:outcomeId>o5qWPZpMkFp</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CHERUB Collaboration</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Database of HIV viral sequences obtained from acutely infected patients (SPARTAC) and end-stage patients (Bloemfontein).</gtr:description><gtr:id>0E1A3A0D-096F-40D0-B899-647AF4A6349C</gtr:id><gtr:impact>A number of publications and presentations - all referenced in the publications section. Collaborations and publications resulting particularly with Goulder and Carlsson</gtr:impact><gtr:outcomeId>AB108998568</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HIV sequence databases</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>On-line software to interpret raw data from digital droplet PCR</gtr:description><gtr:id>C3D0704D-755A-4AA7-9AB3-73B3E9C1469D</gtr:id><gtr:impact>Improved low copy calling of ddPCR outputs
Most downloaded paper in J Virol Methods for first 6 months of 2014</gtr:impact><gtr:outcomeId>P3GjcNBprKn</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Droplet Digitial PCR Open Source Software</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://definetherain.org.uk/</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Repository of 360 samples of plasma and PBMC from acutely infected HIV+ve individuals developed in conjunction with the Wellcome-funded SPARTC trial</gtr:description><gtr:id>0FED9F04-179C-4B25-AABE-540EC88D9536</gtr:id><gtr:impact>With have already published and presented data on early within host and between host HIV adaptation, made possible through this repository. This culminated in a paper in Nature in 2009 (Kawashima et al)</gtr:impact><gtr:outcomeId>BE81FFF9B7E</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Acute HIV samples DNA library</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A repository of around 800 plasma samples from patients in Bloemfontein, South Africa at different stages of HIV clinical progression.</gtr:description><gtr:id>07E01D61-F9D3-4031-85A4-D47C880AC6AB</gtr:id><gtr:impact>FIve papers resulting from this, including Carlson et al Science 2014</gtr:impact><gtr:outcomeId>22D96DDF960</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Bloemfontein sample repository of plasma from AIDS patients</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PBMCs from the SPARTAC trial</gtr:description><gtr:id>FD562E56-6D71-4B9F-9B6F-CEFFCFA0B288</gtr:id><gtr:impact>Publications, documented in portfolio</gtr:impact><gtr:outcomeId>jAgHRApt2ni</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SPARTAC PBMC Repository</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Open source software for analysis of droplet digital PCR data</gtr:description><gtr:id>1ADEBA09-762D-4D69-B524-5D3BA7A62CE2</gtr:id><gtr:impact>Widely accessed. Most downloaded J Virol Methods paper for early 2014</gtr:impact><gtr:outcomeId>54632593287972.96892145</gtr:outcomeId><gtr:title>Definetherain</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EB1B675D-2A11-4C63-9DF4-E7FD2DA6CB5F</gtr:id><gtr:title>A cure for HIV: is it in sight?</gtr:title><gtr:parentPublicationTitle>Expert review of anti-infective therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beb552bb58d9b68654f8911bcd7927a3"><gtr:id>beb552bb58d9b68654f8911bcd7927a3</gtr:id><gtr:otherNames>Pace M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1478-7210</gtr:issn><gtr:outcomeId>54631c13656a64.89782110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D864C9E-B459-4F02-A19C-1830E18D64E0</gtr:id><gtr:title>HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/341e8375fd0b70edf6a5b6519cee6d87"><gtr:id>341e8375fd0b70edf6a5b6519cee6d87</gtr:id><gtr:otherNames>Carlson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>54631c133c43e1.08970175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04431329-E17C-4EDF-927E-52F5C33B7DF1</gtr:id><gtr:title>HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/934ccb890f8b3d4435bbe06cfa0daeeb"><gtr:id>934ccb890f8b3d4435bbe06cfa0daeeb</gtr:id><gtr:otherNames>Frater J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>EzLfyUYctLY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B16D7E3F-1C8F-4BF5-BE4A-B42697C23489</gtr:id><gtr:title>Beating atomic swords into immunological ploughshares.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/934ccb890f8b3d4435bbe06cfa0daeeb"><gtr:id>934ccb890f8b3d4435bbe06cfa0daeeb</gtr:id><gtr:otherNames>Frater J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>KnzmMqZQXCd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3862764A-EE3C-4985-9E63-457E6A8B978E</gtr:id><gtr:title>Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17cc35c67f1f89bfab8c3f77b00113a5"><gtr:id>17cc35c67f1f89bfab8c3f77b00113a5</gtr:id><gtr:otherNames>Payne RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>54631c13ad5fb1.63085924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BEAD07A-39FE-4017-AF61-9185CD588112</gtr:id><gtr:title>Passive sexual transmission of human immunodeficiency virus type 1 variants and adaptation in new hosts.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/670e161ddb05e002f852b23130851c16"><gtr:id>670e161ddb05e002f852b23130851c16</gtr:id><gtr:otherNames>Frater AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D8D1D537A56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A54BDDB3-AFB1-4D56-B722-97F98FC4C5F0</gtr:id><gtr:title>Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, 'definetherain'.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f960dc64663392005f3fbcba53da956"><gtr:id>9f960dc64663392005f3fbcba53da956</gtr:id><gtr:otherNames>Jones M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>54631c1389efe7.00519309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76BB8E16-B1A1-4D66-8AD8-F570C8B83A59</gtr:id><gtr:title>Virus immune evasion: new mechanism and implications in disease outcome.</gtr:title><gtr:parentPublicationTitle>Advances in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88c251aad1523b2ad94ed84e46cadbce"><gtr:id>88c251aad1523b2ad94ed84e46cadbce</gtr:id><gtr:otherNames>Draenert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1687-8639</gtr:issn><gtr:outcomeId>pm_15043_23_23049554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E56B09E-7892-43D7-B378-117B21B515D8</gtr:id><gtr:title>Modelling the evolution and spread of HIV immune escape mutants.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4733c7e44c2264f342e6713e0e09b0be"><gtr:id>4733c7e44c2264f342e6713e0e09b0be</gtr:id><gtr:otherNames>Fryer HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>igzm45aAdnK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70D800AA-8C17-43AE-B0C7-0ECE0FBC8220</gtr:id><gtr:title>Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93aa76e11abaf67e382288e4e0711119"><gtr:id>93aa76e11abaf67e382288e4e0711119</gtr:id><gtr:otherNames>Huang KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>dsuQGFrP4bT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F5AAD5A-4006-40F5-8382-979FCE656744</gtr:id><gtr:title>Widespread impact of HLA restriction on immune control and escape pathways of HIV-1.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/341e8375fd0b70edf6a5b6519cee6d87"><gtr:id>341e8375fd0b70edf6a5b6519cee6d87</gtr:id><gtr:otherNames>Carlson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15043_23_22379086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>380C4BA1-FA70-4C07-B6A8-D664421DEB87</gtr:id><gtr:title>Transmitted Escape Mutations Lead to Accelerated HIV-1 Disease Progression and Largely Define the Relative Contribution of HLA Alleles to Control</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba1c462fc4e2b1ff600f5171518a1667"><gtr:id>ba1c462fc4e2b1ff600f5171518a1667</gtr:id><gtr:otherNames>Carlson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54631c12e4ed31.54501660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47558A1C-2EA8-425E-9709-8132F7F35B05</gtr:id><gtr:title>Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d3d35d367a42471775bc621386670a1"><gtr:id>1d3d35d367a42471775bc621386670a1</gtr:id><gtr:otherNames>English S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>diGP6wRAB5r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C580F775-49C3-4169-AA55-FF976FD9335E</gtr:id><gtr:title>Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8264a54468f390bc6b2d185063824b10"><gtr:id>8264a54468f390bc6b2d185063824b10</gtr:id><gtr:otherNames>Purcell DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>QAPKvAP3KTL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B885AC2D-40E6-4889-8222-E4806FD7A8D1</gtr:id><gtr:title>Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc171515ba5fd88e399ec7ec90cac0eb"><gtr:id>cc171515ba5fd88e399ec7ec90cac0eb</gtr:id><gtr:otherNames>Yager N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15043_23_23095315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E2C61A9-15E0-409A-9A4A-469806A50CDD</gtr:id><gtr:title>Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93aa76e11abaf67e382288e4e0711119"><gtr:id>93aa76e11abaf67e382288e4e0711119</gtr:id><gtr:otherNames>Huang KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>65882544095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B384B5E-972C-4CA0-B976-33B769C43301</gtr:id><gtr:title>HIV control through a single nucleotide on the HLA-B locus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c2d35d76a3ff3436246776122a7aa9"><gtr:id>f5c2d35d76a3ff3436246776122a7aa9</gtr:id><gtr:otherNames>Kl?verpris HN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15043_23_22896606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EC03761-4B20-484C-835A-BB19537D804B</gtr:id><gtr:title>Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15043_23_22952756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D119D35-B21E-4E67-B65C-CFB9CB31BC49</gtr:id><gtr:title>Integrating genealogical and dynamical modelling to infer escape and reversion rates in HIV epitopes.</gtr:title><gtr:parentPublicationTitle>Proceedings. Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74e690d779a5b211ed5b084032909cf4"><gtr:id>74e690d779a5b211ed5b084032909cf4</gtr:id><gtr:otherNames>Palmer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0962-8452</gtr:issn><gtr:outcomeId>pm_15043_23_23677344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1DBB2A6-D9A0-4FF4-BCE9-D312BD34F660</gtr:id><gtr:title>HIV-1 DNA predicts disease progression and post-treatment virological control.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d110ea42909082884b279ca15d700684"><gtr:id>d110ea42909082884b279ca15d700684</gtr:id><gtr:otherNames>Williams JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>54631c13176571.02854141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C360939B-4A5D-4688-BC32-E3518FFB96AC</gtr:id><gtr:title>Co-operative additive effects between HLA alleles in control of HIV-1.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15043_23_23094091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A234870D-5C95-441B-B9C6-8947695E391C</gtr:id><gtr:title>B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93aa76e11abaf67e382288e4e0711119"><gtr:id>93aa76e11abaf67e382288e4e0711119</gtr:id><gtr:otherNames>Huang KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>YvGcW2piqGV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A684E46B-38DC-466D-8D07-09BCDE423B6D</gtr:id><gtr:title>Precise identification of a human immunodeficiency virus type 1 antigen processing mutant.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29b251b9916b74a5d169132969d0fdf5"><gtr:id>29b251b9916b74a5d169132969d0fdf5</gtr:id><gtr:otherNames>Zimbwa P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>B2423B764D5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ED8E438-885D-4A0B-9761-4414EDC50324</gtr:id><gtr:title>Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/670e161ddb05e002f852b23130851c16"><gtr:id>670e161ddb05e002f852b23130851c16</gtr:id><gtr:otherNames>Frater AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>B8125B4AED0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32A516A5-82AB-499F-A5C7-45F1BDB45F4D</gtr:id><gtr:title>Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>AnSHgvf9e2p</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDC83265-BFD8-4142-A4BD-6B0E882189AB</gtr:id><gtr:title>Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54631c14069e30.67403351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0FC8CC1-67B7-42A1-A2D0-DBDC452473BE</gtr:id><gtr:title>New approaches in HIV eradication research.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/934ccb890f8b3d4435bbe06cfa0daeeb"><gtr:id>934ccb890f8b3d4435bbe06cfa0daeeb</gtr:id><gtr:otherNames>Frater J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>cAwR7DNjKFJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BEC87F3-8799-424B-B233-8AA60CEA2577</gtr:id><gtr:title>Short-course antiretroviral therapy in primary HIV infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce76d6881f4431b5a0c18f099ab1deb0"><gtr:id>ce76d6881f4431b5a0c18f099ab1deb0</gtr:id><gtr:otherNames>SPARTAC Trial Investigators</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15043_23_23323897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E5CE000-CC16-4F60-ADBA-D6CB6F09E5A6</gtr:id><gtr:title>CD8+ T-cell responses to different HIV proteins have discordant associations with viral load.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fcba991cefb6af3a5dd59220039ddf0"><gtr:id>7fcba991cefb6af3a5dd59220039ddf0</gtr:id><gtr:otherNames>Kiepiela P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>4F84374B66F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42FCD3D0-9F64-4724-AF3E-A3BA47397850</gtr:id><gtr:title>Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73055ad6fc8dc5247c270fd83a2f168f"><gtr:id>73055ad6fc8dc5247c270fd83a2f168f</gtr:id><gtr:otherNames>Kett DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>Xhq4ezWaPNC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57585144-5C93-4F7F-AE18-1BF90314D99D</gtr:id><gtr:title>Current understanding in HIV immunopathology and treatment.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d110ea42909082884b279ca15d700684"><gtr:id>d110ea42909082884b279ca15d700684</gtr:id><gtr:otherNames>Williams JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>pm_15043_23_22294649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CCA5CB4-12D7-45D4-9E00-AA5173979A3E</gtr:id><gtr:title>Application of magnetic field hyperthermia and superparamagnetic iron oxide nanoparticles to HIV-1-specific T-cell cytotoxicity.</gtr:title><gtr:parentPublicationTitle>International journal of nanomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d110ea42909082884b279ca15d700684"><gtr:id>d110ea42909082884b279ca15d700684</gtr:id><gtr:otherNames>Williams JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1176-9114</gtr:issn><gtr:outcomeId>pm_15043_23_23901272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A5E9E4C-2756-49D9-86E6-A3619C53205B</gtr:id><gtr:title>HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91820a5125b1e7783f9e579697f40998"><gtr:id>91820a5125b1e7783f9e579697f40998</gtr:id><gtr:otherNames>Duda A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>074DAB381E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53FD9C69-2637-4760-9DE2-84E639F887A9</gtr:id><gtr:title>Cytotoxic T-lymphocyte escape mutations identified by HLA association favor those which escape and revert rapidly.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4733c7e44c2264f342e6713e0e09b0be"><gtr:id>4733c7e44c2264f342e6713e0e09b0be</gtr:id><gtr:otherNames>Fryer HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15043_23_22674992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76A519FC-2651-4DFE-B6E7-D521D5B86208</gtr:id><gtr:title>Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15043_23_22313951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F93427BC-A46D-4970-BADA-DC5CB8B4AE3F</gtr:id><gtr:title>Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>LBtFpAvHxfy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FDD68C8-65C5-459C-9246-79AA4DF7774E</gtr:id><gtr:title>HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>VLeUZ6FRSDf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21590140-72F0-43FD-9867-A01BBCC00996</gtr:id><gtr:title>Adaptation of HIV-1 to human leukocyte antigen class I.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d99f9638246ae93c3412e8a61dc7cec4"><gtr:id>d99f9638246ae93c3412e8a61dc7cec4</gtr:id><gtr:otherNames>Kawashima Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>7CABE2DBC1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99EDA5DA-A706-4AE5-97A4-FC064BEDA742</gtr:id><gtr:title>High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5706f9c76e406abe3c614f09d311abc1"><gtr:id>5706f9c76e406abe3c614f09d311abc1</gtr:id><gtr:otherNames>Duncan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>54631c13d1ad34.18429042</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2549F75-941B-479F-8378-416C11F21852</gtr:id><gtr:title>Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45828b86d3e508adeef32e4dda7f4017"><gtr:id>45828b86d3e508adeef32e4dda7f4017</gtr:id><gtr:otherNames>Cosgrove C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15043_23_23255555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61E43CE4-7E11-47BA-A38F-B0E6D848BE72</gtr:id><gtr:title>European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Journal of Crohn's &amp; colitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c3a5142a4491a6c9c844322dda0de0f"><gtr:id>8c3a5142a4491a6c9c844322dda0de0f</gtr:id><gtr:otherNames>Rahier JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1873-9946</gtr:issn><gtr:outcomeId>i85ssUZ9ZgP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16F38F1F-3D06-4941-89C9-632E6A07B07E</gtr:id><gtr:title>Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24fd92235cd67c097015295a80138165"><gtr:id>24fd92235cd67c097015295a80138165</gtr:id><gtr:otherNames>Scherer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_15043_13_15302942</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/626</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>